These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 32794599

  • 1. Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease.
    Vasudevan A, Parthasarathy N, Con D, Nicolaides S, Apostolov R, Chauhan A, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley D, Sparrow MP, Gibson PR, van Langenberg DR.
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1174-1184. PubMed ID: 32794599
    [Abstract] [Full Text] [Related]

  • 2. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
    Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR.
    Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
    [Abstract] [Full Text] [Related]

  • 3. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
    Vasudevan A, Beswick L, Friedman AB, Moltzen A, Haridy J, Raghunath A, Sparrow M, van Langenberg D.
    Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
    [Abstract] [Full Text] [Related]

  • 4. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
    Coskun M, Steenholdt C, de Boer NK, Nielsen OH.
    Clin Pharmacokinet; 2016 Mar; 55(3):257-74. PubMed ID: 26255287
    [Abstract] [Full Text] [Related]

  • 5. Increased risk of thiopurine-related adverse events in elderly patients with IBD.
    Calafat M, Mañosa M, Cañete F, Ricart E, Iglesias E, Calvo M, Rodríguez-Moranta F, Taxonera C, Nos P, Mesonero F, Martín-Arranz MD, Mínguez M, Gisbert JP, García-López S, de Francisco R, Gomollón F, Calvet X, Garcia-Planella E, Rivero M, Martínez-Cadilla J, Argüelles F, Arias L, Cimavilla M, Zabana Y, Domènech E, ENEIDA registry of GETECCU.
    Aliment Pharmacol Ther; 2019 Oct; 50(7):780-788. PubMed ID: 31429097
    [Abstract] [Full Text] [Related]

  • 6. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
    Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A.
    Scand J Gastroenterol; 2017 Sep; 52(9):981-987. PubMed ID: 28554266
    [Abstract] [Full Text] [Related]

  • 7. Toxicity profile of thiopurines in inflammatory bowel disease: a retrospective cohort analysis.
    Labidi A, Hafi M, Ben Mustapha N, Serghini M, Fekih M, Boubaker J.
    Tunis Med; 2020 May; 98(5):404-412. PubMed ID: 32548844
    [Abstract] [Full Text] [Related]

  • 8. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK.
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [Abstract] [Full Text] [Related]

  • 9. Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
    Vasudevan A, Con D, De Cruz P, Sparrow MP, Friedman AB, Garg M, Kashkooli S, Gibson PR, van Langenberg DR.
    Aliment Pharmacol Ther; 2024 Feb; 59(4):504-514. PubMed ID: 38095246
    [Abstract] [Full Text] [Related]

  • 10. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
    Biemans VBC, Savelkoul E, Gabriëls RY, Simsek M, Dijkstra G, Pierik MJ, West RL, de Boer NKH, Hoentjen F.
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1076-1086. PubMed ID: 32339331
    [Abstract] [Full Text] [Related]

  • 11. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
    Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA.
    Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
    [Abstract] [Full Text] [Related]

  • 12. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
    Johnson CM, Dassopoulos T.
    Curr Gastroenterol Rep; 2018 Sep 28; 20(11):53. PubMed ID: 30267281
    [Abstract] [Full Text] [Related]

  • 13. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.
    van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ, Mantzaris G, van Bodegraven AA, Thiopurine Task Force Interest Group.
    Dig Liver Dis; 2011 Apr 28; 43(4):270-6. PubMed ID: 20934926
    [Abstract] [Full Text] [Related]

  • 14. Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.
    Jansen FM, Smits LJT, Thomas PWA, de Jong DJ, Kreijne JE, van Dop WA, den Broeder N, Hoentjen F.
    Dig Dis Sci; 2023 Jul 28; 68(7):2936-2945. PubMed ID: 37131100
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A.
    BMC Gastroenterol; 2020 Sep 11; 20(1):296. PubMed ID: 32917155
    [Abstract] [Full Text] [Related]

  • 16. Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
    Yarur AJ, McGovern D, Abreu MT, Cheifetz A, Papamichail K, Deepak P, Bruss A, Beniwal-Patel P, Dubinsky M, Targan SR, Melmed GY.
    Clin Gastroenterol Hepatol; 2023 Oct 11; 21(11):2908-2917.e10. PubMed ID: 36280102
    [Abstract] [Full Text] [Related]

  • 17. Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: a multicenter cohort study.
    Haisma SM, Lijftogt T, Kindermann A, Damen G, de Ridder L, Escher JC, Mearin ML, de Meij T, Hendriks D, George E, Hummel T, Norbruis O, van Rheenen P.
    J Crohns Colitis; 2015 Apr 11; 9(4):305-11. PubMed ID: 25656249
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
    Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA.
    Inflamm Bowel Dis; 2013 Feb 11; 19(2):363-9. PubMed ID: 22605661
    [Abstract] [Full Text] [Related]

  • 19. Use of thiopurines in inflammatory bowel disease.
    Frei P, Biedermann L, Nielsen OH, Rogler G.
    World J Gastroenterol; 2013 Feb 21; 19(7):1040-8. PubMed ID: 23467510
    [Abstract] [Full Text] [Related]

  • 20. Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease.
    Savelkoul EHJ, Maas MHJ, Bourgonje AR, Crouwel F, Biemans VBC, den Broeder N, Russel MGVM, Römkens TEH, de Boer NK, Dijkstra G, Hoentjen F.
    J Crohns Colitis; 2022 Sep 08; 16(9):1372-1379. PubMed ID: 35303065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.